In Reply
- PMID: 33481517
- DOI: 10.1097/AOG.0000000000004269
In Reply
Conflict of interest statement
Financial Disclosure The authors did not report any potential conflicts of interest.
Comment on
-
Subcutaneous Buprenorphine Extended-Release Use Among Pregnant and Postpartum Women.Obstet Gynecol. 2020 Nov;136(5):902-903. doi: 10.1097/AOG.0000000000004126. Obstet Gynecol. 2020. PMID: 33030872 Free PMC article. Clinical Trial. No abstract available.
-
Subcutaneous Buprenorphine Extended-Release Use Among Pregnant and Postpartum Women.Obstet Gynecol. 2021 Feb 1;137(2):377-378. doi: 10.1097/AOG.0000000000004270. Obstet Gynecol. 2021. PMID: 33481516 No abstract available.
References
-
- Cleary EM, Byron RK, Hinely KA, Talley AW, Costantine MM, Rood KM. Subcutaneous buprenorphine extended-release use among pregnant and postpartum women. Obstet Gynecol 2020;136:902–3. doi: 10.1097/AOG.0000000000004126. - DOI
-
- Arnaudo CL, Andraka-Christou B, Allgood K. Psychiatric co-morbidities in pregnant women with opioid use disorders: Prevalence, impact, and implications for treatment Curr Addict Rep 2017;4:1–3. doi: 10.1007/s40429-017-0132-4. - DOI
-
- ClinicalTrials.gov. Medication treatment for opioid use disorder in expectant mothers (MOMs). Accessed December 1, 2020. https://clinicaltrials.gov/ct2/show/NCT03918850
-
- Jansson LM, Velez ML, McConnell K, Spencer N, Tuten M, Jones H, et al. Maternal buprenorphine treatment and infant outcome. Drug Alcohol Depend 2017;180:56–61. doi: 10.1016/j.drugalcdep.2017.08.001. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources